Volkow, MD JAMA Network Open Key Points Question Are patient-reported outcomes, such as treatment satisfaction with medication, higher among patients treated with weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine? Findings In this open-label randomized ...
In this context, the aim of this study was to assess and compare these inflammatory cell phenotyping in muscle samples of treatment naive juvenile and adult patients with dermatomyositis. Methods: This is a cross-sectional study, in which 28 untreated juvenile and 28 adult untreated dermatomyositis...
poor outcome. In addition to dealing with outcome measures as reported by therapists, which today form the basis for most of what we know in this area [21,23,24] it is essential also to focus on former patients’ perspective of “what works”. Studies exploring which aspects of treatment ...
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6 PubMedGoogle ScholarCrossref 12. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca ...
(CA): elevated ALT level, HBeAg positive or negative; and (3) CHB infection without a strong recommendation to receive antiviral therapy (CAN), including patients during the immune-tolerant phase and those who are in the “grey zones”, meaning that ALT and HBV DNA levels are not in the ...
14, 65, 81, 82, 83, 84, 85, 86, 87, 88 Persistence of a specific IgM response several months after the initial infection was found in some patients with chronic musculoskeletal symptoms.84 The meaning of this phenomenon is not yet clear; according to the most widely accepted hypothesis, ...
The regulatory dataset [consisted of] patients who had pathologically confirmed ROS1-positive, NSCLC with no other drivers. [They were] either TKI naive, meaning they never had received crizotinib or entrectinib, or had progressed on a prior TKI. The drug was given orally as ...
Patients with treatment-naive, metastatic non–small cell lung cancer who had no sensitizing EGFR or ALK genetic alterations were randomized to receive treatment with durvalumab, durvalumab plus tremelimumab, or chemotherapy. Data were collected from July 21, 2015, to October 30, 2018. Interventions ...
Design, Setting, and Participants This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of...
In an embodiment, the pharmaceutical combination and/or the method of treatment and/or the use according to the present invention can be effective for the treatment of naive and relapsed or refractory subjects suffering from cancer or cancerous conditions. In an embodiment, the CDK inhibitor and/...